Interviews - Page 2

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the challenges ahead for the European biosimilars market.
Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses pharmacists' educational needs on biosimilars.
Kashyap Patel, MD, discusses the goals of the Community Oncology Alliance (COA) in forming its biosimilars committee.
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, describes challenges with incorporating biosimilars into cancer care.
Kashyap Patel, MD, discusses considerations for using biosimilar versus subcutaneous rituximab.
Lee Schwartzberg, MD, FACP, The West Clinic, explains the kinds of education that oncology providers still need to feel comfortable with biosimilars. 
Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, discusses her trust's extensive experience with switching patients to biosimilars. 
Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains the Danish experience with biosimilar adalimumab.
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilars could impact the cost of care.
Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes opportunities for biosimilars in the year ahead.
 

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.